The New England Journal of MedicineTumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

A total of 168 patients were randomly assigned to receive tumor-infiltrating lymphocytes (TILs) (84 patients) or ipilimumab (84 patients). The median progression-free survival in the TIL group was 7.2 months and 3.1 months in the ipilimumab group; 49% and 21% of the patients, respectively, had an objective response. The TIL group had a median overall survival of 25.8 months, while the ipilimumab group had a median overall survival of 18.9 months.